Open Access Articles- Top Results for Anandamide


Template:Chembox UNII
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Names

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

IUPAC name
Other names
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Identifiers#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

94421-68-8 7pxN
ChEBI CHEBI:2700 7pxY
ChEMBL ChEMBL15848 7pxY
ChemSpider 4445241 7pxY
IUPHAR ligand 2364
Jmol-3D images Image
MeSH Anandamide
PubChem Template:Chembox PubChem/format
colspan=2 style="background:#f8eaba; border-top:2px solid transparent; border-bottom:2px solid transparent; text-align:center;" #REDIRECTmw:Help:Magic words#Other
This page is a soft redirect. Properties

#REDIRECTmw:Help:Magic words#Other
This page is a soft redirect.-

Molar mass 347.53 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 14pxN verify (what is10pxY/10pxN?)
Infobox references

Anandamide, also known as N-arachidonoylethanolamine or AEA, is an endogenous cannabinoid neurotransmitter. The name is taken from the Sanskrit word (and Hinduistic religious term) ananda, which means "joy, bliss, delight", and amide.[1][2] It is synthesized from N-arachidonoyl phosphatidylethanolamine by multiple pathways.[3] It is degraded primarily by the fatty acid amide hydrolase (FAAH) enzyme, which converts anandamide into ethanolamine and arachidonic acid. As such, inhibitors of FAAH lead to elevated anandamide levels and are being pursued for therapeutic use.[4][5]


Anandamide was isolated and its structure first described in 1992 by W. A. Devane, Lumír Hanuš et al. who were working in a team led by Raphael Mechoulam at the Hebrew University of Jerusalem.[1]

Physiological functions

Anandamide's effects can occur in either the central or peripheral nervous system. These distinct effects are mediated primarily by CB1 cannabinoid receptors in the central nervous system, and CB2 cannabinoid receptors in the periphery.[6] The latter are mainly involved in functions of the immune system. Cannabinoid receptors were originally discovered as being sensitive to Δ9-tetrahydrocannabinol9-THC, commonly called THC), which is the primary psychoactive cannabinoid found in cannabis. The discovery of anandamide came from research into CB1 and CB2, as it was inevitable that a naturally occurring (endogenous) chemical would be found to affect these receptors.

Anandamide has been shown to impair working memory in rats.[7] Studies are under way to explore what role anandamide plays in human behavior, such as eating and sleep patterns, and pain relief.

Anandamide is also important for implantation of the early stage embryo in its blastocyst form into the uterus. Therefore cannabinoids such as Δ9-THC might influence processes during the earliest stages of human pregnancy.[8] Peak plasma anandamide occurs at ovulation and positively correlates with peak estradiol and gonadotrophin levels, suggesting that these may be involved in the regulation of AEA (anandamide) levels.[9] Subsequently, anandamide has been proposed as a biomarker of infertility, but so far lacks any predictive values in order to be used clinically.[10]

Anandamide plays a role in the regulation of feeding behavior, and the neural generation of motivation and pleasure. In addition, anandamide injected directly into the forebrain reward-related brain structure nucleus accumbens enhances the pleasurable responses of rats to a rewarding sucrose taste, and enhances food intake as well.[6][11]

A study published in 1998 shows that anandamide inhibits human breast cancer cell proliferation.[12] Some studies have linked anandamide release as a mechanism of analgesic effects induced by exercise, particularly by running.[13]

In 1996, researchers discovered anandamide in chocolate. They also detected the presence of two substances that might mimic the effects of anandamide, N-oleoylethanolamine and N-linoleoylethanolamine.[14]

Additionally, in 2014 researchers had shown the presence of anandamide and other endocannabinoids in the model organism Drosophila melanogaster (fruit fly), which had previously been unknown, as earlier research had suggested that insects would be incapable of producing these molecules due to a lack of the requisite biochemistry.[15][16]

Synthesis and degradation

The human body synthesizes anandamide from N-arachidonoyl phosphatidylethanolamine (NAPE), which is itself made by transferring arachidonic acid from lecithin to the free amine of cephalin through an N-acyltransferase enzyme.[17][18] Anandamide synthesis from NAPE occurs via multiple pathways and includes enzymes such as phospholipase A2, phospholipase C and NAPE-PLD.[3]

The crystal structure of NAPE-PLD in complex with phosphatidylethanolamine and deoxycholate shows how the cannabinoid anandamide is generated from membrane N-Acylphosphatidylethanolamines (NAPEs), and reveals that bile acids - which are mainly involved in the adsorption of lipids in the small intestine - modulate its biogenesis.[19] These results demonstrate how the production of the endocannabinoid anandamide and other lipid amides, is directly associated with fat digestion.[19]

Endogenous anandamide is present at very low levels and has a very short half-life due to the action of the enzyme fatty acid amide hydrolase (FAAH), which breaks it down into free arachidonic acid and ethanolamine. Studies of piglets show that dietary levels of arachidonic acid and other essential fatty acids affect the levels of anandamide and other endocannabinoids in the brain.[20] High fat diet feeding in mice increases levels of anandamide in the liver and increases lipogenesis.[21] This suggests that anandamide may play a role in the development of obesity, at least in rodents.

Paracetamol (or acetaminophen in the U.S.A.) is metabolically combined with arachidonic acid by FAAH to form AM404.[22] This metabolite of paracetamol is a potent agonist at the TRPV1 vanilloid receptor, a weak agonist at both CB1 and CB2 receptors, and an inhibitor of anandamide reuptake. As a result, anandamide levels in the body and brain are elevated. In this fashion, paracetamol acts as a pro-drug for a cannabimimetic metabolite. This action may be partially or fully responsible for the analgesic effects of paracetamol.[23][24]

There have been identified transport proteins for anandamide and its sister molecule 2-arachidonoylglycerol. These include the heat shock proteins (Hsp70s) and fatty acid binding proteins (FABPs).[25][26]

Medical benefits

The Royal Society of Chemistry have stated that research indicates that AM1172 could potentially be developed into a drug that would increase the brain's anandamide levels to help treat anxiety and depression.[27]

See also


  1. ^ a b Devane, W.; Hanus, L; Breuer, A; Pertwee, R.; Stevenson, L.; Griffin, G; Gibson, D; Mandelbaum, A; Etinger, A; Mechoulam, R (18 December 1992). "Isolation and structure of a brain constituent that binds to the cannabinoid receptor". Science 258 (5090): 1946–1949. PMID 1470919. doi:10.1126/science.1470919. 
  2. ^ Mechoulam R, Fride E (1995). "The unpaved road to the endogenous brain cannabinoid ligands, the anandamides". In Pertwee RG. Cannabinoid receptors. Boston: Academic Press. pp. 233–258. ISBN 0-12-551460-3. 
  3. ^ a b doi:10.1016/j.prostaglandins.2008.12.002
    This citation will be automatically completed in the next few minutes. You can jump the queue or expand by hand
  4. ^ Gaetani, Silvana; Dipasquale, Pasqua; Romano, Adele; Righetti, Laura; Cassano, Tommaso; Piomelli, Daniele; Cuomo, Vincenzo (2009). "The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.". International review of neurobiology 85: 57–72. PMID 19607961. doi:10.1016/S0074-7742(09)85005-8. 
  5. ^ Hwang, Jeannie; Adamson, Crista; Butler, David; Janero, David R.; Makriyannis, Alexandros; Bahr, Ben A. (April 2010). "Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality". Life Sciences 86 (15-16): 615–623. PMC 2848893. PMID 19527737. doi:10.1016/j.lfs.2009.06.003. 
  6. ^ a b Pacher P, Batkai S, Kunos G; Bátkai; Kunos (2006). "The Endocannabinoid System as an Emerging Target of Pharmacotherapy". Pharmacol Rev. 58 (3): 389–462. PMC 2241751. PMID 16968947. doi:10.1124/pr.58.3.2. 
  7. ^ Mallet PE, Beninger RJ; Beninger (1996). "The endogenous cannabinoid receptor agonist anandamide impairs memory in rats". Behavioural Pharmacology 7 (3): 276–284. doi:10.1097/00008877-199605000-00008. 
  8. ^ Piomelli D (January 2004). "THC: moderation during implantation". Nat. Med. 10 (1): 19–20. PMID 14702623. doi:10.1038/nm0104-19. 
  9. ^ El-Talatini MR, Taylor AH, Konje JC; Taylor; Konje (April 2010). "The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle". Fertil. Steril. 93 (6): 1989–96. PMID 19200965. doi:10.1016/j.fertnstert.2008.12.033. 
  10. ^ Rapino, C.; Battista, N.; Bari, M.; Maccarrone, M. (2014). "Endocannabinoids as biomarkers of human reproduction". Human Reproduction Update 20 (4): 501–516. ISSN 1355-4786. PMID 24516083. doi:10.1093/humupd/dmu004. 
  11. ^ Mahler SV, Smith KS, Berridge KC; Smith; Berridge (November 2007). "Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward". Neuropsychopharmacology 32 (11): 2267–78. PMID 17406653. doi:10.1038/sj.npp.1301376. 
  12. ^ De Petrocellis, Luciano; Melck, Dominique; Palmisano, Antonella; Bisogno, Tiziana; Laezza, Chiara; Bifulco, Maurizio; Di Marzo, Vincenzo (7 July 1998). "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation". Proceedings of the National Academy of Sciences 95 (14): 8375–8380. PMC 20983. PMID 9653194. doi:10.1073/pnas.95.14.8375. 
  13. ^
  14. ^ di Tomaso E, Beltramo M, Piomelli D.; Beltramo; Piomelli (Aug 1996). "Brain cannabinoids in chocolate". Nature 382 (6593): 677–8. PMID 8751435. doi:10.1038/382677a0. 
  15. ^ Jeffries K, Dempsey D, Behari A, Anderson R, Merkler D (Nov 2014). "Drosophila melanogaster as a model system to study long-chain fatty acid amide metabolism". FEBS Letters 588 (9): 1596–1602. PMID 24650760. doi:10.1016/j.febslet.2014.02.051. 
  16. ^ McPartland J, Di Marzo V, De Petrocellis L, Mercer A, Glass M. (Aug 2001). "Cannabinoid receptors are absent in insects". Journal of Comparative Neurology 436 (4): 423–429. PMID 11447587. doi:10.1002/cne.1078. 
  17. ^ Natarajan V, Reddy PV, Schmid PC, Schmid HH; Reddy; Schmid; Schmid (August 1982). "N-Acylation of ethanolamine phospholipids in canine myocardium". Biochim. Biophys. Acta 712 (2): 342–55. PMID 7126608. doi:10.1016/0005-2760(82)90352-6. 
  18. ^ Cadas H, di Tomaso E, Piomelli D; Di Tomaso; Piomelli (February 1997). "Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain". J. Neurosci. 17 (4): 1226–42. PMID 9006968. 
  19. ^ a b Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D et al. (Dec 2014). "Structure of Human N-Acylphosphatidylethanolamine-Hydrolyzing Phospholipase D: Regulation of Fatty Acid Ethanolamide Biosynthesis by Bile Acids". Structure 24 (3). doi:10.1016/j.str.2014.12.018. 
  20. ^ Berger, Alvin; Crozier, Gayle; Bisogno, Tiziana; Cavaliere, Paolo; Innis, Sheila; Di Marzo, Vincenzo (15 May 2001). "Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets". Proceedings of the National Academy of Sciences 98 (11): 6402–6406. PMC 33480. PMID 11353819. doi:10.1073/pnas.101119098. 
  21. ^ Osei-Hyiaman, Douglas; DePetrillo, Michael; Pacher, Pál; Liu, Jie; Radaeva, Svetlana; Bátkai, Sándor; Harvey-White, Judith; Mackie, Ken; Offertáler, László; Wang, Lei; Kunos, George (2 May 2005). "Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity". Journal of Clinical Investigation 115 (5): 1298–1305. PMC 1087161. PMID 15864349. doi:10.1172/JCI23057. 
  22. ^ doi:10.1074/jbc.M501489200
    This citation will be automatically completed in the next few minutes. You can jump the queue or expand by hand
  23. ^ Bertolini, Alfio; Ferrari, Anna; Ottani, Alessandra; Guerzoni, Simona; Tacchi, Raffaella; Leone, Sheila (September 2006). "Paracetamol: New Vistas of an Old Drug". CNS Drug Reviews 12 (3-4): 250–275. PMID 17227290. doi:10.1111/j.1527-3458.2006.00250.x. 
  24. ^ Sinning, Christian; Watzer, Bernhard; Coste, Ovidiu; Nüsing, Rolf M.; Ott, Ingo; Ligresti, Alessia; Marzo, Vincenzo Di; Imming, Peter (25 December 2008). "New Analgesics Synthetically Derived from the Paracetamol Metabolite-(4-Hydroxyphenyl)-(5,8,11,14)-icosatetra-5,8,11,14-enamide". Journal of Medicinal Chemistry 51 (24): 7800–7805. PMID 19053765. doi:10.1021/jm800807k. 
  25. ^ Kaczocha, M.; Glaser, S.T.; Deutsch, D.G. (2009). "Identification of intracellular carriers for the endocannabinoid anandamide". Proceedings of the National Academy of Sciences of the United States of America 106 (15): 6375–6380. PMC 2669397. PMID 19307565. doi:10.1073/pnas.0901515106. 
  26. ^ Oddi, S.; Fezza, F.; Pasquariello, N.; D'Agostino, A.; Catanzaro, G.; De Simone, C.; Rapino, C.; Finazzi-Agro, A.; Maccarrone, M. (2009). "Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins". Chemistry & Biology 16 (6): 624–632. PMID 19481477. doi:10.1016/j.chembiol.2009.05.004. 
  27. ^ Evans, Jon (July 2004). "Easing anxiety with anandamide". Chemistry World. 

External links